VOLUNTARY ANNOUNCEMENT: Uni-GLP Development in Treatment of COVID-19 and Other Indications
HONG KONG, CHINA – EQS Newswire – 18 September 2020 – The board of directors (the “Board”) of Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce updates on the developmental potential of the Group’s innovative biologic self-developed drug Recombinant Exendin-4 Injection (“Uni-GLP”). About Uni-GLP Uni-GLP, a class of glucagon-like peptide-1 receptor agonists (“GLP-1 RAs”), can reduce high blood glucose by […]